GURUFOCUS.COM » STOCK LIST » Basic Materials » Chemicals » AlzChem Group AG (XTER:ACT) » Definitions » Capex-to-Revenue

AlzChem Group AG (XTER:ACT) Capex-to-Revenue : 0.00 (As of Mar. 2024)


View and export this data going back to 2011. Start your Free Trial

What is AlzChem Group AG Capex-to-Revenue?

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue.

AlzChem Group AG's Capital Expenditure for the three months ended in Mar. 2024 was €0.00 Mil. Its Revenue for the three months ended in Mar. 2024 was €150.06 Mil.

Hence, AlzChem Group AG's Capex-to-Revenue for the three months ended in Mar. 2024 was 0.00.


AlzChem Group AG Capex-to-Revenue Historical Data

The historical data trend for AlzChem Group AG's Capex-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AlzChem Group AG Capex-to-Revenue Chart

AlzChem Group AG Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Capex-to-Revenue
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.11 0.08 - - -

AlzChem Group AG Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Capex-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - 0.03 - - -

Competitive Comparison of AlzChem Group AG's Capex-to-Revenue

For the Specialty Chemicals subindustry, AlzChem Group AG's Capex-to-Revenue, along with its competitors' market caps and Capex-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


AlzChem Group AG's Capex-to-Revenue Distribution in the Chemicals Industry

For the Chemicals industry and Basic Materials sector, AlzChem Group AG's Capex-to-Revenue distribution charts can be found below:

* The bar in red indicates where AlzChem Group AG's Capex-to-Revenue falls into.



AlzChem Group AG Capex-to-Revenue Calculation

AlzChem Group AG's Capex-to-Revenue for the fiscal year that ended in Dec. 2023 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 540.649
=0.00

AlzChem Group AG's Capex-to-Revenue for the quarter that ended in Mar. 2024 is calculated as

Capex-to-Revenue=- Capital Expenditure / Revenue
=- (0) / 150.064
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


AlzChem Group AG  (XTER:ACT) Capex-to-Revenue Explanation

Capex-to-Revenue measures a company's investments in physical assets such as property, industrial buildings or equipment to its revenue. The ratio shows how aggressively the company reinvests its revenue back into productive assets. However, a high ratio potentially indicates that the company has invested too much in innovation and infrastructure, taking up funds that could be used to boost productivity and increase revenue. Therefore, a high Capex to Revenue Ratio could be a positive or a negative sign depending on how effectively a company converts those investments into future earnings.


AlzChem Group AG Capex-to-Revenue Related Terms

Thank you for viewing the detailed overview of AlzChem Group AG's Capex-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


AlzChem Group AG (XTER:ACT) Business Description

Traded in Other Exchanges
Address
Dr.-Albert-Frank-Street 32, Trostberg, DEU, 83308
AlzChem Group AG is an international chemical company. Its reportable segments are Specialty Chemicals, Basics and Intermediates, and Other Holdings. The specialty chemicals segment focuses on the production and distribution of high-quality growth products, and the basics and intermediates segment covers the production of basic and intermediate products. It generates a majority of its revenue from the Specialty Chemical segment. Geographically it serves Europe, Asia, and the Rest of the world whilst deriving substantial revenue from Germany.

AlzChem Group AG (XTER:ACT) Headlines

From GuruFocus

Enact to Host Fourth Quarter 2022 Earnings Call February 7th

By GlobeNewswire GlobeNewswire 01-06-2023

Enact Receives Ratings Upgrade from Fitch Ratings

By sperokesalga sperokesalga 04-25-2023

Enact Welcomes Jerome Upton to its Board of Directors

By sperokesalga sperokesalga 03-02-2023

Enact To Participate at the Bank of America 2023 Financial Services Conference

By Stock market mentor Stock market mentor 02-03-2023

Enact Enters Into $200 Million Revolving Credit Facility

By GuruFocusNews GuruFocusNews 07-07-2022

Enact Announces Quarterly Dividend

By PurpleRose PurpleRose 08-11-2022

Enact Releases 2023 Environmental, Social, and Governance (ESG) Roadmap

By Stock market mentor Stock market mentor 01-26-2023